Prognostic clinical indicators in patients with metastatic castration-resistant prostate cancer treated with radium-223 plus enzalutamide: Data from patients in J-RAP-BSI trial.

Authors

Kazuhiro Kitajima, Junpei Kuyama, Takashi Kawahara, Tsuyoshi Suga, Tomoaki Otani, Shigeyasu Sugawara, Yumiko Kono, Yukihisa Tamaki, Ayumi Seko-Nitta, Yoshinobu Ishiwata, Kimiteru Ito, Akira Toriihara, Shiro Watanabe, Makoto Hosono, Shingo Yamamoto, Mitsuhiro Narita, Koichiro Yamakado

Published in

Hellenic journal of nuclear medicine. Aug 06, 2026. Epub Aug 06, 2026.

Abstract

To investigate clinical factors associated with prognosis in patients with metastatic castration-resistant prostate cancer (mCRPC) and bone metastases treated with radium-223 dichloride (²²³Ra) and enzalutamide combination therapy.
This retrospective study included a cohort of 71 mCRPC patients in Japan who underwent combination therapy with ²²³Ra and enzalutamide at 14 hospitals and had pretreatment bone scintigraphy findings available for analysis. Associations of overall survival (OS) with clinicopathological factors, including Eastern Cooperative Oncology Group (ECOG) performance status, hemoglobin, alkaline phosphatase (ALP), lactate dehydrogenase (LDH), prostate-specific antigen (PSA), PSA doubling time, automated bone scan index (aBSI), and previous chemotherapy history, were assessed using the Cox proportional hazards model and log-rank testing.
Sixty (84.5%) of the 71 patients enrolled completed six cycles of ²²³Ra. The mean follow-up period was 21.9 months (range, 3.9-62.9 months), during which 35 patients (49.3%) died. Univariate analysis demonstrated that low hemoglobin (<12g/dL, P<0.0001), high PSA (≥20ng/mL, P<0.0001), ALP above the normal range (P=0.0067), and high aBSI (≥2.0%, P=0.0006) were significantly associated with shorter OS. In multivariable analysis, low hemoglobin [hazard ratio (HR) 5.52, 95% confidence interval (CI) 2.32-14.2, P<0.0001] and high PSA (HR 3.06, 95% CI 1.07-9.78, P=0.037) were identified as significant prognostic factors for OS.
In patients with mCRPC treated with ²²³Ra and enzalutamide combination therapy, pretreatment hemoglobin and PSA levels may serve as useful surrogate biomarkers for predicting overall survival.

PMID:
42555489
Bibliographic data and abstract were imported from PubMed on 06 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.